Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Signs Licensing, Research Deals with BMS, Abbott

NEW YORK, Jan. 21 (GenomeWeb News) - Iconix Pharmaceuticals has signed research and technology licensing deals with Bristol-Myers Squibb and Abbott Laboratories, the company said today.


Both companies will have access to Iconix's DrugMatrix chemogenomics database, listing genomic effects of drugs and chemicals, and to its genomic biomarkers for potential toxicity and side effects of drug candidates, called Drug Signatures.


BMS plans to use Iconix's chemogenomics technology in several research projects each year to prioritize candidate drugs, and to study the toxicity and mechanisms of new compounds before, during, and after pre-clinical development. Under the agreement with BMS, valued at $24 million, Mountain View, Calif.-based Iconix will receive an upfront payment, technology license fees, project fees, and commercialization milestone payments.


Abbott wants to utilize Iconix's technology to identify biomarkers for the clinical development and commercialization of drugs. In addition, both companies plan to develop cell-based gene expression screening tests for early stage compounds to assess their potential liver toxicity. Iconix said it may commercialize this platform in the future.

Abbott will pay Iconix an upfront fee, technology access fees, research funding, and clinical milestones.


The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.